<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4182155</article-id><article-id pub-id-type="publisher-id">1129-2377-15-S1-I7</article-id><article-id pub-id-type="doi">10.1186/1129-2377-15-S1-I7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>EHMTI-0364. Non-invasive vagus nerve stimulation using gammacore&#x000ae; for prevention and acute treatment of chronic cluster headache: report from the randomized phase of the preva study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Gaul</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Diener</surname><given-names>H</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Solbach</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Silver</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Straube</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Magis</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Reuter</surname><given-names>U</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Andersson</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Liebler</surname><given-names>EJ</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib></contrib-group><aff id="I1"><label>1</label>Migraine and Headache Clinic, University of Duisburg-Essen, K&#x000f6;nigstein, Germany</aff><aff id="I2"><label>2</label>Department of Neurology, University Hospital Essen, Essen, Germany</aff><aff id="I3"><label>3</label>Department of Neurology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK</aff><aff id="I4"><label>4</label>Department of Neurology, Ludwig Maximilian University of Munich, Munich, Germany</aff><aff id="I5"><label>5</label>Department of Neurology, Li&#x000e8;ge University, Li&#x000e8;ge, Belgium</aff><aff id="I6"><label>6</label>Berlin NeuroImaging Center, Charit&#x000e9; University Hospital, Berlin, Germany</aff><aff id="I7"><label>7</label>Clinical Affairs, electroCore Medical, Gothenburg, Sweden</aff><aff id="I8"><label>8</label>Scientific Medical and Clinical Affairs, electroCore LLC, Basking Ridge, USA</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2014</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014</named-content><named-content content-type="supplement-sponsor">Publication costs for this supplement were funded by the conference.</named-content></supplement><fpage>I7</fpage><lpage>I7</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Gaul et al; licensee Springer.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Gaul et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/15/S1/I7"/><conference><conf-date>18-21 September 2014</conf-date><conf-name>4th European Headache and Migraine Trust International Congress: EHMTIC 2014</conf-name><conf-loc>Copenhagen, Denmark</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Cluster headache (CH) is a painful and debilitating disorder for which non-invasive vagus nerve stimulation (nVNS) may be a treatment option.</p></sec><sec><title>Aim</title><p>Compare the efficacy of gammaCore&#x000ae;, a handheld nVNS device, with the standard of care (SoC) in chronic CH subjects in the randomized phase of the Prevention and Acute (PREVA) Treatment of Chronic Cluster Headache study.</p></sec><sec sec-type="methods"><title>Methods</title><p>PREVA was a multicenter study comprised of 3 phases: 2-week run-in, 4-week randomized (1:1; nVNS vs SoC), and 4-week extension. Subjects randomized to nVNS delivered stimulations prophylactically twice daily (mandatory) and optionally for the rescue treatment of CH attack. The primary efficacy end point was the reduction in number of CH attacks/week during the last 2 weeks of the randomized phase versus the run-in phase. Additional end points included the proportion of subjects with &#x0003e;50% reduction in CH attacks/week (response rate) and rescue medication use; safety was assessed by monitoring the frequency of adverse events.</p></sec><sec sec-type="results"><title>Results</title><p>Ninety-seven subjects were randomized; data from 93 subjects (n=45 nVNS; n=48 SoC) were included in the intention-to-treat population. Number of CH attacks/week was significantly reduced in subjects treated with nVNS compared with patients treated with SoC only (-7.6 vs -2.0; P=.002). Further, significantly more nVNS- than SoC-treated subjects were considered treatment responders (34.4% vs 7.1%; P=.003). nVNS was associated with less use of rescue medications and demonstrated a favorable safety/tolerability profile.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Prophylactic treatment of chronic CH with nVNS is safe and, compared with SoC, reduces frequency of CH attacks/week. Sham-controlled studies are warranted and underway to confirm these data.</p><p>Abstract submitted on behalf of the PREVA Study Investigators.</p></sec></body></article>